Protalix BioTherapeutics (PLX) Net Cash Flow Growth (3y) (2013 - 2026)
Protalix BioTherapeutics (PLX) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -35.85% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 106.37% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 67.39% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -70.95% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 52.78% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.55% |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | -43.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.00% |
| Mar 31, 2026 | 18.24% |
| Dec 31, 2025 | -45.06% |
| Sep 30, 2025 | -33.71% |
| Jun 30, 2025 | 39.28% |
| Mar 31, 2025 | 76.30% |
| Dec 31, 2024 | -31.47% |
| Sep 30, 2024 | 45.04% |
| Jun 30, 2024 | -31.42% |
| Mar 31, 2024 | 30.93% |
| Dec 31, 2023 | -11.51% |
| Sep 30, 2023 | -73.27% |
| Jun 30, 2023 | 53.56% |
| Mar 31, 2023 | 86.13% |
| Dec 31, 2022 | 55.42% |
| Sep 30, 2022 | 21.56% |
| Jun 30, 2022 | -9.95% |
| Mar 31, 2022 | -42.41% |
| Dec 31, 2021 | 109.69% |
| Sep 30, 2021 | -55.13% |